# US 2019/0169129 A1 · Deuterated cftr potentiators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169129 A1
- Document ID: US20190169129A1
- Status: Published application
- Kind: A1
- Application number: 16/033,802
- Filed: 2018-07-12
- Published: 2019-06-06
- Earliest claimed: 2011-05-18
- Assignees: Vertex Pharmaceuticals (Europe) Limited
- Applicants: Vertex Pharmaceuticals (Europe) Limited
- Inventors: Adam J. Morgan
- Web page: https://patentgrep.com/patent/US20190169129A1

## CPC

- C07D 215/56: with oxygen atoms in position 4
- C07B 59/002: {Heterocyclic compounds}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

## Claims

### Claim at position 1

-19. (canceled)

### Claim 20

A process for preparing Compound 106
or a pharmaceutically acceptable salt thereof, comprising reacting Compound 12
with Compound 6
wherein any atom not designated as deuterium is present at its natural isotopic abundance, wherein the percentage of isotopic enrichment for each designated deuterium is at least 90%, and
optionally treating Compound 106 with a base to produce a pharmaceutically acceptable salt of Compound 106.

### Claim 21 (depends on 20)

The process of claim 20, wherein the reaction of Compound 12 with Compound 6 is performed in the presence of a coupling agent and base.

### Claim 22 (depends on 21)

The process of claim 21, wherein the coupling agent is (N,N,N′,N′)-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate and the base is N,N′-diisopropylethylamine.

### Claim 23 (depends on 20)

The process of claim 20, wherein Compound 12 is produced by converting Compound 10
into Compound 12

### Claim 24 (depends on 23)

The process of claim 23, wherein Compound 10 is converted to Compound 12 with a reducing agent.

### Claim 25 (depends on 24)

The process of claim 24, wherein the reducing agent is an acid.

### Claim 26 (depends on 25)

The process of claim 25, wherein the acid is HCl.

### Claim 27 (depends on 20)

The process of claim 20, wherein Compound 9
is converted into Compound 10

### Claim 28 (depends on 27)

The process of claim 27, wherein Compound 9 is converted to Compound 10 in the presence of a reducing agent and metal catalyst.

### Claim 29 (depends on 28)

The process of claim 28, wherein the reducing agent is ammonium formate and the metal catalyst is, palladium on carbon.

### Claim 30 (depends on 20)

The process of claim 20, wherein Compound 9 is produced by converting Compound 8
into Compound 9

### Claim 31 (depends on 30)

The process of claim 30, wherein Compound 8 is reacted with HNO3/H2SO4 to form a nitrated product.

### Claim 32 (depends on 31)

The process of claim 31, wherein the nitration product is subjected to potassium hydroxide in methanol to form Compound 9.

### Claim 33 (depends on 20)

The process of claim 20, wherein Compound 8 is produced by converting Compound 7
into Compound 8

### Claim 34 (depends on 33)

The process of claim 33, wherein the conversion of Compound 7 into Compound 8 is performed in the presence of an acyloxycarbonylating agent and base.

### Claim 35 (depends on 34)

The process of claim 34, wherein the acyloxycarbonylating agent is methyl chloroformate and the base is triethylamine.

### Claim 36 (depends on 33)

The process of claim 33, wherein the conversion of Compound 7 into Compound 8 is performed in the presence of 4-dimethylaminopyridine.

### Claim 37 (depends on 20)

The process of claim 20, wherein the process further comprises converting tert-butyl phenol
into Compound 7

### Claim 38 (depends on 37)

The process of claim 37, wherein the conversion of tert-butyl phenol into Compound 7 is performed in the presence of a source of X—C(CD3)3 and an acid,

### Claim 39 (depends on 38)

The process of claim 38, wherein the source of X—C(CD3)3 is tert-butanol-d10 and the acid is D2SO4.